Medtronic (NYSE:MDT) has won FDA approval for a deep brain stimulation system for Parkinson’s disease. The approval is for BrainSense Adaptive deep brain stimulation (DBS)and BrainSense Electrode ...

The FDA approved Medtronic's BrainSense Adaptive DBS and Electrode Identifier for Parkinson's, enhancing therapy personalization and clinic efficiency.

The approval was the first of an adaptive DBS device for Parkinson’s, Medtronic said in a Monday announcement. Medtronic claims the launch of the system will be the largest ever commercial ...

"Medtronic is the only company in the world to offer an adaptive DBS system that dynamically adjusts therapy in real time," said Brett Wall, executive vice president and president of the ...

Medtronic's Percept™ DBS neurostimulators now incorporate BrainSense™ Adaptive technology, which allows the system to automatically adjust therapy without manual intervention by patients or ...

Medtronic gets US FDA nod for the world’s first adaptive deep brain stimulation system for people with Parkinson’s disease: Galway, Ireland Saturday, March 1, 2025, 09:00 Hrs ...

Medtronic (MDT) announced FDA approval of BrainSense Adaptive deep brain stimulation – aDBS – and BrainSense Electrode Identifier. There is no cure for debilitating neurological conditions like ...

The U.S. Food and Drug Administration has approved Medtronic's deep brain stimulation system for use in patients with Parkinson's disease, the medical device maker said on Monday.

Medtronic's Percept™ DBS neurostimulators now incorporate BrainSense™ Adaptive technology, which allows the system to automatically adjust therapy without manual intervention by patients or clinicians ...